אינג'י 10 מג20 מג טבליות

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

EZETIMIBE; SIMVASTATIN

Disponível em:

MERCK SHARP & DOHME ISRAEL LTD

Código ATC:

C10AA01

Forma farmacêutica:

טבליה

Composição:

EZETIMIBE 10 MG; SIMVASTATIN 20 MG

Via de administração:

פומי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

MERCK SHARP & DOHME (ITALIA) S.P.A.

Grupo terapêutico:

SIMVASTATIN

Área terapêutica:

SIMVASTATIN

Indicações terapêuticas:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Data de autorização:

2012-04-30